-
Je něco špatně v tomto záznamu ?
Dual-Phase Dual-Energy CT in Patients Treated with Erlotinib for Advanced Non-Small Cell Lung Cancer: Possible Benefits of Iodine Quantification in Response Assessment
J. Baxa, T. Matouskova, G. Krakorova, B. Schmidt, T. Flohr, M. Sedlmair, J. Bejcek, J. Ferda,
Jazyk angličtina Země Německo
Typ dokumentu časopisecké články
NLK
ProQuest Central
od 1997-01-01 do 2017-12-31
CINAHL Plus with Full Text (EBSCOhost)
od 2008-01-01 do Před 1 rokem
Medline Complete (EBSCOhost)
od 2000-01-01 do Před 1 rokem
Nursing & Allied Health Database (ProQuest)
od 1997-01-01 do 2017-12-31
Health & Medicine (ProQuest)
od 1997-01-01 do 2017-12-31
- MeSH
- erlotinib terapeutické užití MeSH
- jod MeSH
- lidé středního věku MeSH
- lidé MeSH
- lymfatické metastázy MeSH
- lymfatické uzliny diagnostické zobrazování MeSH
- nádory plic farmakoterapie patologie MeSH
- nemalobuněčný karcinom plic diagnóza farmakoterapie sekundární MeSH
- počítačová rentgenová tomografie metody MeSH
- pozitronová emisní tomografie metody MeSH
- protinádorové látky terapeutické užití MeSH
- reprodukovatelnost výsledků MeSH
- senioři MeSH
- staging nádorů * MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
OBJECTIVES: To investigate the relationship of dual-phase dual-energy CT (DE-CT) and tumour size in the evaluation of the response to anti-EGFR therapy in patients with advanced non-small cell lung cancer (NSCLC). METHODS: Dual-phase DE-CT was performed in 31 patients with NSCLC before the onset of anti-EGFR (erlotinib) therapy and as follow-up (mean 8 weeks). Iodine uptake (IU; mg/mL) was quantified using prototype software in arterial and venous phases; arterial enhancement fraction (AEF) was calculated. The change of IU before and after therapy onset was compared with anatomical evaluation in maximal transverse diameter and volume (responders vs. non-responders). RESULTS: A significant decrease of IU in venous phase was proved in responders according to all anatomical parameters (p=0.002-0.016). In groups of non-responders, a significant change of IU was not proved with variable trends of development. The most significant change was observed using the anatomical parameter of volume (cut-off 73 %). A significant difference of percentage change in AEF was proved between responding and non-responders (p=0.019-0.043). CONCLUSION: Dual-phase DE-CT with iodine uptake quantification is a feasible method with potential benefit in advanced assessment of anti-EGFR therapy response. We demonstrated a decrease in vascularization in the responding primary tumours and non-significant variable development of vascularization in non-responding tumours. KEY POINTS: • Dual-phase DE-CT is feasible for vascularization assessment of NSCLC with anti-EGFR therapy. • There was a significant decrease of iodine uptake in responding tumours. • There was a non-significant and variable development in non-responding tumours. • There was significant difference of AEF percentage change between responders and non-responders.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17014224
- 003
- CZ-PrNML
- 005
- 20170428104712.0
- 007
- ta
- 008
- 170413s2016 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s00330-015-4092-6 $2 doi
- 035 __
- $a (PubMed)26563350
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Baxa, Jan $u Department of Imaging Methods, Faculty of Medicine and University Teaching Hospital in Pilsen, Pilsen, Czech Republic. baxaj@fnplzen.cz.
- 245 10
- $a Dual-Phase Dual-Energy CT in Patients Treated with Erlotinib for Advanced Non-Small Cell Lung Cancer: Possible Benefits of Iodine Quantification in Response Assessment / $c J. Baxa, T. Matouskova, G. Krakorova, B. Schmidt, T. Flohr, M. Sedlmair, J. Bejcek, J. Ferda,
- 520 9_
- $a OBJECTIVES: To investigate the relationship of dual-phase dual-energy CT (DE-CT) and tumour size in the evaluation of the response to anti-EGFR therapy in patients with advanced non-small cell lung cancer (NSCLC). METHODS: Dual-phase DE-CT was performed in 31 patients with NSCLC before the onset of anti-EGFR (erlotinib) therapy and as follow-up (mean 8 weeks). Iodine uptake (IU; mg/mL) was quantified using prototype software in arterial and venous phases; arterial enhancement fraction (AEF) was calculated. The change of IU before and after therapy onset was compared with anatomical evaluation in maximal transverse diameter and volume (responders vs. non-responders). RESULTS: A significant decrease of IU in venous phase was proved in responders according to all anatomical parameters (p=0.002-0.016). In groups of non-responders, a significant change of IU was not proved with variable trends of development. The most significant change was observed using the anatomical parameter of volume (cut-off 73 %). A significant difference of percentage change in AEF was proved between responding and non-responders (p=0.019-0.043). CONCLUSION: Dual-phase DE-CT with iodine uptake quantification is a feasible method with potential benefit in advanced assessment of anti-EGFR therapy response. We demonstrated a decrease in vascularization in the responding primary tumours and non-significant variable development of vascularization in non-responding tumours. KEY POINTS: • Dual-phase DE-CT is feasible for vascularization assessment of NSCLC with anti-EGFR therapy. • There was a significant decrease of iodine uptake in responding tumours. • There was a non-significant and variable development in non-responding tumours. • There was significant difference of AEF percentage change between responders and non-responders.
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a protinádorové látky $x terapeutické užití $7 D000970
- 650 _2
- $a nemalobuněčný karcinom plic $x diagnóza $x farmakoterapie $x sekundární $7 D002289
- 650 _2
- $a erlotinib $x terapeutické užití $7 D000069347
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a jod $7 D007455
- 650 _2
- $a nádory plic $x farmakoterapie $x patologie $7 D008175
- 650 _2
- $a lymfatické uzliny $x diagnostické zobrazování $7 D008198
- 650 _2
- $a lymfatické metastázy $7 D008207
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 12
- $a staging nádorů $7 D009367
- 650 _2
- $a pozitronová emisní tomografie $x metody $7 D049268
- 650 _2
- $a reprodukovatelnost výsledků $7 D015203
- 650 _2
- $a počítačová rentgenová tomografie $x metody $7 D014057
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Matouskova, Tana $u Department of Imaging Methods, Faculty of Medicine and University Teaching Hospital in Pilsen, Pilsen, Czech Republic.
- 700 1_
- $a Krakorova, Gabriela $u Department of Pulmonary Diseases, Faculty of Medicine and University Teaching Hospital in Pilsen, Pilsen, Czech Republic.
- 700 1_
- $a Schmidt, Bernhard $u Siemens Healthcare, CT division, Forchheim, Germany.
- 700 1_
- $a Flohr, Thomas $u Siemens Healthcare, CT division, Forchheim, Germany.
- 700 1_
- $a Sedlmair, Martin $u Siemens Healthcare, CT division, Forchheim, Germany.
- 700 1_
- $a Bejcek, Jiri $u Department of Imaging Methods, Faculty of Medicine and University Teaching Hospital in Pilsen, Pilsen, Czech Republic.
- 700 1_
- $a Ferda, Jiri $u Department of Imaging Methods, Faculty of Medicine and University Teaching Hospital in Pilsen, Pilsen, Czech Republic.
- 773 0_
- $w MED00009646 $t European radiology $x 1432-1084 $g Roč. 26, č. 8 (2016), s. 2828-36
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/26563350 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20170413 $b ABA008
- 991 __
- $a 20170428105033 $b ABA008
- 999 __
- $a ok $b bmc $g 1200689 $s 975002
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 26 $c 8 $d 2828-36 $e 20151112 $i 1432-1084 $m European radiology $n Eur Radiol $x MED00009646
- LZP __
- $a Pubmed-20170413
